Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ecopipam in Tourette's Disorder
NCT05615220Phase 3Completed
- Sponsor
- Emalex Biosciences
- Start
- Jan 2023
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 12
01
Overview
A Phase 3 trial of ecopipam in Tourette syndrome (TS), sponsored by Emalex Biosciences. Started Jan 2023; status: completed.
02
Drugs
ecopipam
03
Conditions
Tourette syndrome (TS)
Beyond the preview
Go deeper on NCT05615220.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05615220.